Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Vascular Biology

Background:

• Hypertension is a major risk factor for peripheral vascular disease (PVD), comparable in importance to coronary artery disease.
• Investigating drug efficacy in occlusive vascular disease presents unique challenges due to patient comorbidities and the need for specific study designs.

Purpose of the Study:

• To highlight the complexities in designing drug trials for peripheral vascular disease.
• To discuss the critical factors influencing study design, including placebo control, crossover, treatment duration, and dosage.
• To explore the potential of carvedilol in managing hypertension and PVD based on its hemodynamic profile.

Main Methods:

• Emphasizes the necessity of placebo-controlled, crossover study designs for occlusive vascular disease.
• Stresses the importance of critical treatment phase length due to high risk of other vascular events.
• Recommends drug dose titration to achieve similar antihypertensive effects and includes patient training in treadmill procedures.

Main Results:

• Resting blood flow may appear normal in PVD due to compensatory arteriolar vasodilation, masking reduced perfusion pressure.
• Regional circulation distal to blockages is sensitive to perfusion pressure changes.
• Potential risks of vasodilator agents, like the 'steal' phenomenon, and conflicting data on beta-blockers are noted.

Conclusions:

• The unique hemodynamic profile of carvedilol, a beta-blocker/vasodilator, suggests theoretical benefits for patients with hypertension and PVD.
• Further clinical studies are needed to validate the practical efficacy of carvedilol in this patient population.
• Careful study design, including functional assessments like claudication distance, is crucial for evaluating interventions in PVD.